Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00730405 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis
A Phase 2 study, sponsored by Stiefel, a GSK Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 582
- Enrollment target
NCT00730405: Completed Phase 2 study, sponsored by Stiefel, a GSK Company.
NCT00730405 is a Phase 2 study that has completed, run by Stiefel, a GSK Company. The registered enrollment target is 582 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (338% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00730405, a Phase 2 study, has completed, sponsored by Stiefel, a GSK Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 582 participants
- Enrollment target
Study Summary
Phase 2 study to examine how the study drug works and its side effects in subjects with toenail fungus.
Primary Outcome
At each study visit, the investigator assessed the percentage of affected toenail on the target nail by estimating the percent affected nail in each quadrant, summing the percent affected in each quadrant and dividing the sum by 4. Effective treatment was defined as a mycological cure and clear or almost clear nail (distal subungual hyperkeratosis and/or onycholysis leaving less than 10% of nail plate effected). Comparisons were carried out in a sequential step-down fashion, combined with the Ho
Interventions
- DRUG Albaconazole 100mg
- DRUG Albaconazole 200mg
- DRUG Albaconazole 400mg
- DRUG Placebo 400 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 582 participants |
| Start Date | 2008-07-16 |
| Est. Completion | 2010-02-19 |
| Phase | Phase 2 |
What the finished NCT00730405 record still lists
NCT00730405 is an interventional study that assigns participants to a tested intervention. The registered 582 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (338% higher).
The record links to 0 conditions, and to 4 interventions - of which Albaconazole 100mg is the first listed.
NCT00730405 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00730405 about?
NCT00730405 is a clinical study titled "Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis". Phase 2 study to examine how the study drug works and its side effects in subjects with toenail fungus.
What is the current status of trial NCT00730405?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 582 participants. The study started on 2008-07-16. Estimated completion is 2010-02-19.
What interventions are being tested in trial NCT00730405?
The interventions under investigation include: Albaconazole 100mg (DRUG), Albaconazole 200mg (DRUG), Albaconazole 400mg (DRUG), Placebo 400 mg (DRUG).
Who is sponsoring clinical trial NCT00730405?
This trial is sponsored by Stiefel, a GSK Company, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00730405's enrollment target sits among peer trials
582 58th of 2000 higher than 1,943 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06350097 · 582 participants · Phase 3
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- NCT06563895 · 582 participants · Phase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- NCT06819007 · 582 participants · Phase 3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- NCT03840083 · 584 participants · NA
Sleep-dependent Learning in Aging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI